REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
<em>The review of safety of monoclonal anti-ige-antibodies (xolair) — a new medication for the treatment of severe allergic bronchial asthma is presented. Local and system adverse events, originating after injection of medicament in clinical studies and following administration in patients are...
Main Author: | A.V. Emel'yanov |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2008-01-01
|
Series: | Вопросы современной педиатрии |
Online Access: | http://vsp.spr-journal.ru:80/jour/article/view/1462 |
Similar Items
-
REVIEW OF SAFETY AND TOLERANCE OF OMALIZUMAB
by: A.V. Emel'yanov
Published: (2008-10-01) -
Urticaria and angioedema as possible reactions of omalizumab
by: Ozlem Ozbagcivan, et al.
Published: (2018-03-01) -
VII All-Russia Scientific and Practical Congress Healthcare priority national project, problems facing pediatric endocrinology in connectionwith its implementation, 1-2 June 2009, Sankt-Peterburg
by: Andrey Olegovich Emel'yanov
Published: (2009-09-01) -
Vsemirnyy den' bol'nogo sakharnym diabetom
by: Andrey Olegovich Emel'yanov
Published: (2008-12-01) -
World Diabetes Day
by: Andrey Olegovich Emel'yanov
Published: (2009-12-01)